Physician profile
Robert A Osterhoff
NPI 1801028907
$5,332.39
in general payments reported to CMS, 2019-2025
23 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.84 · 2020: $209 · 2021: $658 · 2022: $1,167 · 2023: $1,022 · 2024: $1,250 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983 · Consulting Fee: $200 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.96 |
| Consulting Fee | $200.00 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,434.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $458.79 | 2020-2024 | Entyvio |
| Janssen Biotech, INC. | $414.68 | 2022-2024 | Stelara, Tremfya |
| Pfizer INC. | $268.85 | 2019-2025 | |
| Lilly USA, LLC | $228.94 | 2024-2025 | Omvoh |
| Neptune Medical INC. | $200.00 | 2023 | |
| Celltrion USA INC. | $178.92 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Nestle Healthcare Nutrition INC. | $176.28 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $133.57 | 2021-2024 | Dificid |
| Qol Medical, LLC | $120.56 | 2023-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $119.72 | 2021-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $107.91 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $92.10 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $86.97 | 2019-2023 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.69 | 2021-2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $53.31 | 2024 | Bylvay |
| Phathom Pharmaceuticals, INC. | $36.79 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $34.92 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $31.77 | 2024 | Idacio |
| Genzyme Corporation | $28.79 | 2023 | |
| Alfasigma USA, INC. | $19.69 | 2020 | |
| Gilead Sciences, INC. | $18.07 | 2020 | |
| Medtronic, INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Osterhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.